Vesilute vs Carnosine
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- Admin Route
- SubQ, Oral
- Oral, Topical
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 1,000–2,000 mg
- Frequency
- Daily for 10–30 days
- Once to twice daily with meals
- Key Benefits
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Potent anti-glycation (prevents protein cross-linking/aging)
- Broad-spectrum antioxidant in muscle and brain
- Extends cell lifespan and protects telomeres
- Improves muscle performance and delays fatigue (pH buffering)
- Neuroprotective against Alzheimer's amyloid-beta
- Wound healing acceleration
- Anti-cataract properties (eye health)
- Improves diabetes complications via AGE prevention
- Chelates excess copper and zinc
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Very well tolerated
- Rare: mild GI discomfort at high doses
- No significant adverse effects in human studies
- Stacks With
- —
- —